Drugs / Human Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02780895 | May 2014 → Dec 2017 | Parkinson disease | Celavie Bioscences, LLC | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01497002 | Apr 2005 → Jul 2018 | acute myeloid leukemia | University of Leipzig | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780895 ↗ |
| Action | Restore | “replacing damaged/destroyed cells of the brain, and/or stimulating the patient's brain to repair itself” NCT02780895 ↗ |
| Modality | Cell therapy | “Allogeneic stem cell transplantation using reduced intensity conditioning” NCT01497002 ↗ |
| Route | Other | “intraputaminal cell implantation” NCT02780895 ↗ |